Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP1A1 | P05023 | 3/20 | 1.00 |
| ▸ | ATP1B1 | P05026 | 3/20 | 1.00 |
| ▸ | ATP1A3 | P13637 | 3/20 | 1.00 |
| ▸ | ATP1B2 | P14415 | 3/20 | 1.00 |
| ▸ | ATP1A2 | P50993 | 3/20 | 1.00 |
| ▸ | ATP1B3 | P54709 | 3/20 | 1.00 |
| ▸ | FXYD2 | P54710 | 3/20 | 1.00 |
| ▸ | ATP1A4 | Q13733 | 3/20 | 1.00 |
| ▸ | NUDT1 | P36639 | 1/20 | 1.00 |
| ▸ | ACE | P12821 | 2/20 | 0.70 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.70 |
| ▸ | MET | P08581 | 1/20 | 0.62 |
| ▸ | PKLR | P30613 | 1/20 | 0.58 |
| ▸ | GALNT2 | Q10471 | 1/20 | 0.58 |
| ▸ | GALNT1 | Q10472 | 1/20 | 0.58 |
| ▸ | GALNT3 | Q14435 | 1/20 | 0.58 |
| ▸ | GALNT10 | Q86SR1 | 1/20 | 0.58 |
| ▸ | GALNT13 | Q8IUC8 | 1/20 | 0.58 |
| ▸ | GALNT6 | Q8NCL4 | 1/20 | 0.58 |
| ▸ | GALNT14 | Q96FL9 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30451609 | 1.00 | ATP1A1 (1.00) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL151934 | 0.89 | ATP1A1 (1.00) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL7227954 | 0.89 | ATP1A1 (0.79) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL3874869 | 0.85 | ATP1A1 (0.74) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL7238197 | 0.85 | ATP1A1 (0.72) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL7330918 | 0.83 | ACE (1.00) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| 3,4-Dihydroxyxanthone SCHEMBL30668688 | 0.83 | PTGS2 (1.00) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| 3,4-Dihydroxyxanthone SCHEMBL133422 | 0.83 | PTGS2 (1.00) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL152329 | 0.82 | ACE (0.73) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL23240704 | 0.78 | ATP1A1 (0.64) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11654292-B2 | Targeted osmotic lysis of malignant cancer cells using pulsed magnetic field gradients | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2023-05-23 | — | — | US | claimed |
| US-20200147405-A1 | TARGETED OSMOTIC LYSIS OF MALIGNANT CANCER CELLS USING PULSED MAGNETIC FIELD GRADIENTS | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2020-05-14 | — | — | US | claimed |
| EP-2477494-B1 | NA/K-ATPASE LIGANDS, OUABAIN ANTAGONISTS, ASSAYS AND USES THEREOF | UNIV TOLEDO (US) | 2015-11-11 | — | — | EP | claimed |
| CN-104968799-A | Assays and cell-based tests using a receptor na/k-atpase/src complex and uses thereof | UNIV TOLEDO | 2015-10-07 | — | — | CN | claimed |
| US-20150272923-A1 | Na/K-ATPase Ligands, Ouabain Antagonists, Assays and Uses Thereof | THE UNIVERSITY OF TOLEDO (US) | 2015-10-01 | — | — | US | claimed |
| US-9114126-B2 | Na/K-ATPase ligands, ouabain antagonists, assays and uses thereof | THE UNIVERSITY OF TOLEDO (US) | 2015-08-25 | — | — | US | claimed |
| US-20150233925-A1 | Assays and Cell-Based Tests Using a Receptor Na/K-ATPase/Src Complex and Uses Thereof | THE UNIVERSITY OF TOLEDO (US) | 2015-08-20 | — | — | US | claimed |
| US-9062022-B2 | Polymer composition and dialysis membrane formed from the polymer composition | THE UNIVERSITY OF AKRON (US) | 2015-06-23 | — | — | US | claimed |
| US-20140031419-A1 | Na/K-ATPase Ligands, Ouabain Antagonists, Assays and Uses Thereof | THE UNIVERSITY OF TOLEDO (US) | 2014-01-30 | — | — | US | claimed |
| WO-2013169931-A2 | ASSAYS AND CELL-BASED TESTS USING A RECEPTOR NA/K-ATPASE/SRC COMPLEX AND USES THEREOF | THE UNIVERSITY OF TOLEDO (US) | 2013-11-14 | — | — | WO | claimed |
| EP-2373638-A1 | POLYMER COMPOSITION AND DIALYSIS MEMBRANE FORMED FROM THE POLYMER COMPOSITION | The University of Akron (US) | 2011-10-12 | — | — | EP | claimed |
| US-20110233138-A1 | POLYMER COMPOSITION AND DIALYSIS MEMBRANE FORMED FROM THE POLYMER COMPOSITION | THE UNIVERSITY OF AKRON | 2011-09-29 | — | — | US | claimed |
| WO-2010065484-A1 | POLYMER COMPOSITION AND DIALYSIS MEMBRANE FORMED FROM THE POLYMER COMPOSITION | THE UNIVERSITY OF AKRON (US) | 2010-06-10 | — | — | WO | claimed |
| EP-0888052-A4 | XANTHONE ANALOGS FOR THE TREATMENT OF INFECTIOUS DISEASES | INTERLAB CORP (US) | 2002-05-22 | — | — | EP | claimed |
| EP-0888052-A1 | XANTHONE ANALOGS FOR THE TREATMENT OF INFECTIOUS DISEASES | INTERLAB CORPORATION (US) | 1999-01-07 | — | — | EP | claimed |
| WO-1997034482-A1 | XANTHONE ANALOGS FOR THE TREATMENT OF INFECTIOUS DISEASES | INTERLAB CORP. (US) | 1997-09-25 | — | — | WO | claimed |
| US-20240316085-A1 | METHODS, AGENTS, AND DEVICES FOR LOCAL NEUROMODULATION OF AUTONOMIC NERVES | Tulavi Therapeutics, Inc. | 2024-09-26 | — | — | US | disclosed |
| US-12029733-B2 | Treatment of sepsis and related inflammatory conditions by local neuromodulation of the autonomic nervous system | Tulavi Therapeutics, Inc. (US) | 2024-07-09 | — | — | US | disclosed |
| EP-0888052-A1 | XANTHONE ANALOGS FOR THE TREATMENT OF INFECTIOUS DISEASES | INTERLAB CORPORATION (US) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997034482-A1 | XANTHONE ANALOGS FOR THE TREATMENT OF INFECTIOUS DISEASES | INTERLAB CORP. (US) | 1997-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150272923-A1 | Na/K-ATPase Ligands, Ouabain Antagonists, Assays and Uses Thereof | ATP1A2, ATP1B1, ATP1A1 | ATP1A1 3/4885ATP1B1 2/4885ATP1A3 7/4885 |
| US-20140031419-A1 | Na/K-ATPase Ligands, Ouabain Antagonists, Assays and Uses Thereof | ATP1A2, ATP1B1, ATP1A1 | ATP1A1 3/4885ATP1B1 2/4885ATP1A3 7/4885 |
| US-20110233138-A1 | POLYMER COMPOSITION AND DIALYSIS MEMBRANE FORMED FROM THE POLYMER COMPOSITION | PROC, LNPK, F10 | ATP1A1 2528/4885ATP1B1 2752/4885ATP1A3 2950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.